Ratings Lonza Group AG Börse Stuttgart

Equities

LO3A

US54338V1017

Delayed Börse Stuttgart Other stock markets 09:43:46 2024-06-27 am EDT			5-day change	1st Jan Change
49.4 ^EUR	-0.40%		0.00%	+34.78%

Jun. 20	Berenberg Lifts Price Target on Lonza Group, Maintains Buy Recommendation	MT
May. 14	Swiss Market Index Edges Up Ahead of Inflation Report	MT

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's high margin levels account for strong profits.
Sales forecast by analysts have been recently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.51 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
LONZA GROUP AG	+34.78%	39.08B	-
MODERNA, INC.	+21.31%	46.93B	B-
IQVIA HOLDINGS INC.	-8.11%	38.48B	B
ALNYLAM PHARMACEUTICALS, INC.	+29.42%	31.01B	B
CELLTRION, INC.	-13.75%	26.14B	C
ICON PUBLIC LIMITED COMPANY	+11.11%	25.88B	B-
MEDPACE HOLDINGS, INC.	+36.08%	12.53B	C+
BIO-TECHNE CORPORATION	-6.85%	11.36B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.68%	10.65B	C+
QIAGEN N.V.	-8.49%	9.04B	A

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes